Drug intelligence / Profile preview

LGG + L. rhamnosus LC705 + Bifidobacterium breve Bbi99 + propionibacterium freudenreichii

Development stage
Unknown
Lead developer
Chr. Hansen
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

This product is a multi-strain probiotic combination containing four specific bacterial strains: - Lactobacillus rhamnosus GG (LGG) - Lactobacillus rhamnosus LC705 - Bifidobacterium breve Bbi99 - Propionibacterium freudenreichii These strains are used together as a live biotherapeutic product, primarily as a dietary supplement to support gut health and modulate the intestinal microbiome. Each strain has been studied for its ability to colonize the gastrointestinal tract, outcompete pathogenic bacteria, enhance gut barrier function, and modulate immune responses. LGG is one of the most clinically documented probiotic strains worldwide and is associated with benefits such as reducing antibiotic-associated diarrhea, improving symptoms of irritable bowel syndrome (IBS), supporting immune function, preventing certain infections (e.g., respiratory tract infections in children), and restoring microbiome balance after disturbances like antibiotic use[1][2][4][5]. The other included strains—L. rhamnosus LC705, B. breve Bbi99, and P. freudenreichii—are also recognized for their roles in maintaining or restoring healthy gut flora.

Beyond the preview

Go deeper on LGG + L. rhamnosus LC705 + Bifidobacterium breve Bbi99 + propionibacterium freudenreichii.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LGG + L. rhamnosus LC705 + Bifidobacterium breve Bbi99 + propionibacterium freudenreichii.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call